Drugs / Metaiodobenzylguanidine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01313936 | Mar 2011 → May 2014 | neuroblastoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05514106 | May 2023 → Sep 2026 overdue | Lewy body dementia, REM sleep behavior disorder, cognitive impairment with or without cerebellar ataxia, parkinsonian disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01370330 | — | neuroblastoma | Kieuhoa Vo | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metaiodobenzylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01370330 ↗ |
| Known as | MIBG | “meta-iodobenzylguanidine (MIBG) (123I)” NCT05514106 ↗ |
| Modality | Diagnostic / imaging agent | “1 administration of 123I-MIBG for a single SPECT scan” NCT05514106 ↗ |
| Route | Intravenous | “will be infused intravenously through a patient's central line” NCT01370330 ↗ |